Rubedo’s Topical Cream Cuts Skin Biological Age by Two Years in Early Trial
Rubedo Life Sciences reported that its experimental topical cream reduced the biological age of participants' skin by an average of two years after four weeks of use. The treatment targets cellular senescence, a process where damaged cells stop dividing but remain active, contributing to inflammation and tissue damage. In a small trial involving 11 people with atopic dermatitis, the drug also increased specific collagen levels by 10 percent and lowered inflammation markers. While one participant showed an 11-year reduction in skin age, experts caution that epigenetic clocks do not necessarily prove functional youth or longevity. The company is expanding trials to other skin conditions and exploring oral formulations for metabolic issues.
Key points
- Rubedo Life Sciences presented data at the Aging Research and Drug Discovery meeting in Boston showing its topical cream reduced skin biological age by an average of two years in a four-week trial.
- The trial involved 11 participants with atopic dermatitis, an inflammatory skin condition, and used an independent aging clock developed by Mitra Bio to measure epigenetic changes.
- The drug targets cellular senescence by temporarily disabling the GPX4 protein, which makes senescent cells susceptible to ferroptosis, a regulated form of cell death, while reviving nearby stressed cells.
- Results included a 10 percent increase in collagen associated with skin elasticity and a reduction in inflammation-related markers, with one participant experiencing an 11-year drop in skin age.
- A separate trial of 18 people with actinic keratosis showed a 46 percent reduction in skin lesions after one month of treatment.
- Rubedo is expanding research to psoriasis, sun-damaged skin, and hereditary hair loss, with plans to develop an over-the-counter version and an oral pill for metabolic conditions.
Background
This development follows recent studies highlighting the limitations and potential of epigenetic aging clocks. In September 2026, a Yale study confirmed that drugs like metformin and semaglutide lower biological age markers, though researchers noted this does not guarantee longer life. Similarly, earlier trials of the drug rentosertib for idiopathic pulmonary fibrosis showed significant reductions in biological age across multiple clocks, but experts emphasized that these biomarker shifts do not prove actual aging reversal or reduced disease risk. The current Rubedo trial adds to a growing body of evidence that targeting cellular senescence may influence aging trajectories, though the field remains cautious about translating epigenetic data into clinical outcomes for healthy populations.
Why it matters
The potential for a topical treatment to reverse biological markers of aging could reshape the skincare and longevity industries. If Rubedo’s drug proves effective in larger trials, it could offer a new class of anti-aging products beyond traditional retinoids, potentially addressing both cosmetic concerns and underlying inflammatory conditions. However, the reliance on epigenetic clocks as primary metrics remains a point of contention, with experts warning that functional health and visible skin quality are the ultimate measures of success for consumers.
What to watch
Rubedo Life Sciences plans to expand its clinical trials to include psoriasis, sun-damaged skin, and androgenetic alopecia. The company is also developing an oral formulation to test for metabolic conditions associated with aging and is exploring a lower-potency, over-the-counter version for general skin aging. Larger, longer-term studies are needed to determine if reductions in epigenetic age translate to improved skin function and longevity.
Want the full story? Read the original reporting
Read on WIRED